Teleflex

Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry

Retrieved on: 
Thursday, November 16, 2023
TAVR, Safety, NYSE, TFX, Cardiology, Structural heart disease, Patient, Registry, Interventional cardiology, Intervention, Hemostasis, SAFE, Teleflex, Doctor of Philosophy, Mount Sinai Medical Center, VCD, Mount Sinai Hospital (Manhattan), Medical device, Medical imaging, Hospital, Surgery, MD

The registry will include appropriate patient selection and proper vascular access.

Key Points: 
  • The registry will include appropriate patient selection and proper vascular access.
  • Enrolling at least 250 patients in up to 15 major TAVR institutions across the US and Canada, the ACCESS-MANTA™ Registry is an international, multicenter, prospective, observational, single-arm clinical registry.
  • “Large bore access site complications are recognized as morbid,1 driving increased costs and prolonged length-of-stay,2” said Teleflex Interventional Medical Director, Christopher Buller, MD.
  • “We are excited that Mount Sinai Medical Center is spearheading the Teleflex ACCESS-MANTA™ Registry,” said Dr. Khera, Co-Global Principal Investigator.

Large-Scale Real-World Study Demystifies UroLift™ System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments

Retrieved on: 
Tuesday, November 14, 2023
Prostate, Nature, NYSE, WVTT, Aes, TFX, MIST, PUL, Paper, Patient, TURP, Prostate cancer, Mount Sinai Health System, Isabella Tree, MD, BPH, Teleflex, PVP, Medical imaging, Medicine, Urology

However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.

Key Points: 
  • However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.
  • This first-of-its-kind study overcomes these limitations and directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments.
  • * The retreatment rate for UroLift™ PUL (11.6%) is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift™ System.
  • Under this definition, at one-year procedural complications were lowest following the UroLift™ System (15%) and highest following Rezūm™ WVTT (26%).

Global Tax Management Welcomes Ed Coleman to its Executive Leadership Team

Retrieved on: 
Wednesday, December 13, 2023
Finance, Consulting, Accounting, Professional Services, Other Professional Services, Master, KPMG, Tax, Associate, Multimedia, GTM, Documentation, Villanova University, PwC, ERP, Teleflex, Growth, Health, Business analytics, Fortune 500, Sales Tax Management Services, Ed

Global Tax Management (GTM), a professional services firm focused exclusively on delivering corporate tax services, announced today that former Big 4 partner Ed Coleman joins its executive leadership team as a Managing Director.

Key Points: 
  • Global Tax Management (GTM), a professional services firm focused exclusively on delivering corporate tax services, announced today that former Big 4 partner Ed Coleman joins its executive leadership team as a Managing Director.
  • Prior to joining GTM, Ed spent 25 years at KPMG, most recently serving as a Tax Partner within the firm’s Business Tax Services corporate practice in Philadelphia for almost a decade.
  • “Ed is a natural fit to serve GTM’s multinational client base in addressing their complex tax matters,” said Dave Sekula, CEO and Executive Director of GTM.
  • “I look forward to working with the GTM team as we continue to deliver co-sourced and outsourced tax services to an increasing client base.”

MedTech Innovator Crowns Medipixel Top 2023 Innovator in Grand Finals Competition of Asia Pacific Accelerator

Retrieved on: 
Monday, December 11, 2023
Technology, Medical Devices, Finance, Health Technology, Professional Services, Cardiology, Health, Data Analytics, Artificial Intelligence, Senior, COE, Cardiovascular disease, Patient, Ecosystem, Q&A, Conference, Mentorship, Diagnosis, Growth, Medtech, Heart, Ophthalmology, AI, Physician, Innovation, Enterprise, Johnson & Johnson, Consultant, Cambridge Consultants, Partnership, Business development, Siemens Healthineers, Death, SWITCH, Human, Airline, Management, Video game, Nursing, Pharmaceutical industry, Teleflex

The winning company was determined by a live audience vote during the MedTech Innovator Asia Pacific 2023 Grand Finals hosted by MedTech Innovator in partnership with APACMed at the APACMed MedTech Forum , 5-6 December, in Singapore.

Key Points: 
  • The winning company was determined by a live audience vote during the MedTech Innovator Asia Pacific 2023 Grand Finals hosted by MedTech Innovator in partnership with APACMed at the APACMed MedTech Forum , 5-6 December, in Singapore.
  • During the APACMed MedTech Forum, all 24 accelerator companies were showcased to the conference attendees, representing the key leadership of the Asia Pacific medtech industry.
  • MedTech Innovator’s Asia Pacific Accelerator sponsors and partners include Johnson & Johnson MedTech, Olympus, Teleflex, Siemens Healthineers, B Braun Medical, Cambridge Consultants, Jabil Healthcare and Enterprise Singapore, and dozens of community partners .
  • The MedTech Innovator Asia Pacific Program is held in partnership with APACMed.

Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)

Retrieved on: 
Wednesday, December 6, 2023
Class Action Lawsuit, Professional Services, Legal, TFX, Helmsley Building, Teleflex, Suite, NYSE, GPM

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws.
  • If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20231206043134/en/

Global Vascular Access Devices (MedSuite) Market Size, Share & Trends Analysis 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, PICC, Teleflex, Central venous catheter, Acquisition, Research, BD (company), Risk, Catheter, Peripherally inserted central catheter, CVC, Growth, Bard (company), Medical imaging, Medical device

The "Global Vascular Access Devices Market Size, Share & Trends Analysis 2024-2030 - MedSuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vascular Access Devices Market Size, Share & Trends Analysis 2024-2030 - MedSuite" report has been added to ResearchAndMarkets.com's offering.
  • While this MedSuite report provides a comprehensive overview of the Global Vascular Access Devices market, you also have the option to access each market segment individually as stand-alone MedCore reports.
  • The global vascular access device market is on the brink of substantial expansion, and long-term devices like implantable ports, CVCs, and PICCs are emerging as the primary drivers of this growth.
  • In 2023, Becton Dickinson continued to maintain its dominant position as the leader in the global vascular access device and accessories market.

Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Medical Devices, Health, Health Technology, Managed Care, Organization, History, Patient, Piper Sandler Companies, Conference, Growth, Management, Teleflex

Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations.

Key Points: 
  • Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations.
  • Mr. Smith previously held senior positions at Sensium Healthcare Ltd., Teleflex, Hillrom Holdings and ZOLL Medical Corporation.
  • “Inogen is a global leader in portable oxygen therapy solutions, with a large and growing market, and leading patient-centric product portfolio,” said Elizabeth Mora, Chairperson of the Board.
  • I believe Inogen has a solid foundation, with leading products, and significant potential to make innovative respiratory solutions the standard of care to improve patient health.

Teleflex Announces Quarterly Dividend

Retrieved on: 
Thursday, November 2, 2023
Teleflex, NYSE, TFX, Holding company, Security (finance)

WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.

Key Points: 
  • WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
  • The dividend is payable December 15, 2023, to shareholders of record at the close of business on November 15, 2023.
  • Additional information about Teleflex can be obtained from the company’s website at teleflex.com .

Teleflex Announces Third Quarter 2023 Earnings Conference Call Information

Retrieved on: 
Thursday, October 19, 2023
Teleflex, Telephone, ID, Utility location, NYSE, TFX

WAYNE, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 2, 2023.

Key Points: 
  • WAYNE, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 2, 2023.
  • To participate in the conference call, please utilize this link to pre-register and receive the dial-in information.
  • An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 2, 2023, either on the Teleflex website or by telephone.
  • The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 647 362 9199 (all other locations).The conference ID is 87648.

Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

Retrieved on: 
Friday, October 20, 2023
United States Court of Appeals for the Federal Circuit, Patent, Vanda, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Teleflex, Public, Pharmacy, Apotex Inc v Sanofi-Synthelabo Canada Inc, Patient, Generic drug

Vanda's petition seeks to show that the Federal Circuit's approach to obviousness has deviated materially from KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007), which trains the obviousness inquiry on whether the claimed innovations "do more than yield a predictable result."

Key Points: 
  • Vanda's petition seeks to show that the Federal Circuit's approach to obviousness has deviated materially from KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007), which trains the obviousness inquiry on whether the claimed innovations "do more than yield a predictable result."
  • Vanda believes that the Federal Circuit's approach improperly invalidates critical patent rights, which are necessary to ensure robust pharmaceutical research and development.
  • "Properly calibrated patent protection is essential to pharmaceutical innovation, which is in turn critical for advances in public health.
  • Chief Justice Roberts extended the time for the filing of Vanda's forthcoming petition, which Vanda expects to file by January 12, 2024.